Stock Analysis

ZIM Laboratories Third Quarter 2025 Earnings: EPS: ₹0.82 (vs ₹0.98 in 3Q 2024)

NSEI:ZIMLAB
Source: Shutterstock

ZIM Laboratories (NSE:ZIMLAB) Third Quarter 2025 Results

Key Financial Results

  • Revenue: ₹980.8m (up 1.9% from 3Q 2024).
  • Net income: ₹40.0m (down 16% from 3Q 2024).
  • Profit margin: 4.1% (down from 5.0% in 3Q 2024). The decrease in margin was driven by higher expenses.
  • EPS: ₹0.82 (down from ₹0.98 in 3Q 2024).
earnings-and-revenue-history
NSEI:ZIMLAB Earnings and Revenue History February 12th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

ZIM Laboratories' share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for ZIM Laboratories you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if ZIM Laboratories might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:ZIMLAB

ZIM Laboratories

Engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally.

Excellent balance sheet with questionable track record.

Community Narratives

Priced for AI perfection - cracks are emerging
Fair Value US$90.15|47.31% overvalued
ChadWisperer
ChadWisperer
Community Contributor
NVDA Market Outlook
Fair Value US$341.12|61.068999999999996% undervalued
NateF
NateF
Community Contributor
Karoon Energy (ASX:KAR) - Buy Baby Buy 🚀
Fair Value AU$5.10|70.392% undervalued
StockMan
StockMan
Community Contributor